TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The method further comprises: curing the compressed granules of step (d). The granules of step (a) are milled prior to step (b). The granules having a mean size of 100 mu m to 2 mm are selected in step (b). In the method: additional active agent is provided in substantially pure form; compression takes place directly after blending with no further intermediate steps; curing takes place at 40-100 degrees C and for 10 minute to 3 hours; and at least two active agents are blended with granules of step (a) or (b). Preferred Components: The active agent is an opioid agonist or antagonist, preferably oxycodone, hydromorphone, hydrocodone, tramadol, oxymorphone, naltrexone, or naloxone or their salts, hydrates or solvates. The first active agent is an opioid agonist, preferably oxycodone, hydromorphone, hydrocodone, tramadol or oxymorphone, and the second active ingredient is an opioid antagonist, preferably naloxone, naltrexone or nalmefene. The obtained dosage form releases the active agent(s) with the in vitro release when measured using the Ph. Eur. paddle method in Simulated Gastric Fluid (500 or 1000 ml) at 100 rpm at 37 degrees C is: 10-60 wt.% of active agent(s) at 0.5 hours; 30-80 wt.% wt.% of active agent(s) at 1 hour; 35-85 wt.% of active agent(s) at 2 hours; 40-95 wt.% of active agent(s) at 3 hours; 50-100 wt.% of active agent(s) at 4 hours; 60-100 wt.% of active agent(s) at 5 hours; 70-100 wt.% of active agent(s) at 6 hours; 80-100 wt.% of active agent(s) at 8 hours; or 85-100 wt.% of active agent(s) at 12 hours. The ratio of the amount of active agent released after 0.5, 1 or 2 hours of in vitro dissolution of the dosage form in 500 or 1000 ml of Simulated Gastric Fluid pH 1.2 with up to 40% ethanol using the Ph. Eur. paddle method at 100 rpm at 37 degrees C compared to the amount of active agent released after 0.5, 1 or 2 hours of in vitro dissolution of the dosage form in 500 or 1000 ml of Simulated Gastric Fluid pH 1.2 with 0% ethanol using the Ph. Eur. paddle method at 100 rpm at 37 degrees C is 2:1 or less, preferably 1:5 or less.    TECHNOLOGY FOCUS - POLYMERS - Preferred Components: The prolonged release material is hydrophobic or hydrophilic polymers, protein-derived material, gums, waxes, oils, fatty acids or fatty alcohols. The polymers are cellulose ethers or (meth)acrylic acid (co)polymers. EXAMPLE - Hypromellose 5.2 mPas was mixed with purified water until fully dissolved using a Silverson high shear mixer. Then, whilst heating to 60 degrees C and maintaining mixing, glycerol monostearate (40-55%) was added. When the mixture reached 60 degrees C, heating was discontinued the mixture was cooled to less than 54 degrees C with continued mixing. Talc was added to the Eudragit NE 40 D (RTM: Neutral copolymer based on ethyl acrylate and methyl methacrylate) dispersion while stirring with a Heidolph paddle stirrer until fully dispersed. Then the hypromellose/glycerol monostearate dispersion was added to the Eudragit NE 40 D (RTM: Neutral copolymer based on ethyl acrylate and methyl methacrylate)/talc dispersion with paddle stirring until a homogenous mixture was obtained. Stirring was maintained. Ethylcellulose and lactose monohydrate was placed into fluid bed granulator and the granulating dispersion added. The granules were then dried in the fluidized bed granulator at less than 28 degrees C for 20-30 minutes until the moisture content was below 2 wt.%. Subsequently the granules were milled to give granulating dispersion. The granules were blended with hydromorphone hydrochloride and naloxone hydrochloride, Eudragit RSPO (RTM: Release modifier) and magnesium stearate, and the blend was compressed using a Kilian rotary tablet press at a tablet speed of up to 50000 tablets/hour.